Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imiquimod + Zalifrelimab - UroGen Pharma

Next Previous
Drug Profile

Imiquimod + Zalifrelimab - UroGen Pharma

Alternative Names: UGN-201 + UGN-301; UGN-302

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UroGen Pharma
  • Developer Agenus; UroGen Pharma
  • Class Aminoquinolines; Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Small molecules
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunostimulants; T lymphocyte stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bladder cancer

Most Recent Events

  • 28 May 2024 No recent reports of development identified for preclinical development in Bladder-cancer in USA (Intravesicular)
  • 31 Jul 2022 UroGen Pharma concludes the collaboration with MD Anderson for non clinical development of imiquimod + zalifrelimab as the research objectives achieved before July 2022
  • 18 Mar 2021 UroGen and the University of Texas MD Anderson Cancer Center plans non-clinical studies for imiquimod + zalifrelimab in the first half of 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top